Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Review

Gankyrin regulates cell signaling network

Authors: Xinxin Wang, Bin Jiang, Yanjie Zhang

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53. Although Gankyrin overexpression was identified in different carcinomas eventually and associated with poor prognosis, its function and mechanism remain not well understood. Recently, the signal transduction mechanisms of Gankyrin have been explored, which may provide new drug targets in tumors overexpressing Gankyrin. In this review, we summarize the significant signal transduction pathways regulated by Gankyrin.
Literature
1.
Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med. 2000;6:96–9.CrossRefPubMed
2.
Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and rb. Cancer Cell. 2005;8:3–4.CrossRefPubMed
3.
Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. Gankyrin: a new oncoprotein and regulator of prb and p53. Trends Cell Biol. 2006;16:229–33.CrossRefPubMed
4.
Li JN, Tsai MD. Novel insights into the ink4-cdk4/6-rb pathway: Counter action of gankyrin against ink4 proteins regulates the cdk4-mediated phosphorylation of rb. Biochemistry. 2002;41:3977–83.CrossRefPubMed
5.
Dawson S, Apcher S, Mee M, Higashitsuji H, Baker R, Uhle S, et al. Gankyrin is an ankyrin-repeat oncoprotein that interacts with cdk4 kinase and the s6 atpase of the 26 S proteasome. J Biol Chem. 2002;277:10893–902.CrossRefPubMed
6.
Mahajan A, Guo Y, Yuan CH, Weghorst CM, Tsai MD, Li JN. Dissection of protein-protein interaction and cdk4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and p16. J Mol Biol. 2007;373:990–1005.CrossRefPubMedPubMedCentral
7.
Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, et al. The oncoprotein gankyrin binds to mdm2/hdm2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005;8:75–87.CrossRefPubMed
8.
Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY, et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatol (Baltim, Md). 2011;54:1259–72.CrossRef
9.
Wang GL, Shi X, Haefliger S, Jin J, Major A, Iakova P, et al. Elimination of c/ebp(alpha) through the ubiquitin-proteasome system promotes the development of liver cancer in mice. J Clin Investig. 2010;120:2549–62.CrossRefPubMedPubMedCentral
10.
Liu Y, Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Koike K, et al. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (fih-1) and activating hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2013;432:22–7.CrossRefPubMed
11.
Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, et al. Gankyrin plays an essential role in ras-induced tumorigenesis through regulation of the rhoa/rock pathway in mammalian cells. J Clin Investig. 2010;120:2829–41.CrossRefPubMedPubMedCentral
12.
Wang WP, Yan XL, Li WM, Ni YF, Zhao JB, Lu Q, et al. Clinicopathologic features and prognostic implications of gankyrin protein expression in non-small cell lung cancer. Pathol Res Pract. 2015;211:939–47.CrossRefPubMed
13.
Jing H, Zhang G, Meng L, Meng Q, Mo H, Tai Y. Gradually elevated expression of gankyrin during human hepatocarcinogenesis and its clinicopathological significance. Sci Rep. 2014;4:5503.PubMedPubMedCentral
14.
Zhao X, Fu J, Xu A, Yu L, Zhu J, Dai R, et al. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the rac1/jnk pathway. Cell Death Dis. 2015;6:e1751.CrossRefPubMedPubMedCentral
15.
Liu Y, Zhang J, Qian W, Dong Y, Yang Y, Liu Z, et al. Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasis. PLoS One. 2014;9:e95043.CrossRefPubMedPubMedCentral
16.
Kim YH, Kim JH, Choi YW, Lim SK, Yim H, Kang SY, et al. Gankyrin is frequently overexpressed in breast cancer and is associated with erbb2 expression. Exp Mol Pathol. 2013;94:360–5.CrossRefPubMed
17.
Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai ZF, et al. Gankyrin promotes breast cancer cell metastasis by regulating rac1 activity. Oncogene. 2013;32:3452–60.CrossRefPubMed
18.
Gao L, Xie H, Dong L, Zou J, Fu J, Gao X, et al. Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells. Mol Med Rep. 2014;9:1032–6.PubMed
19.
Tang S, Yang G, Meng Y, Du R, Li X, Fan R, et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther. 2010;9:2.
20.
Ortiz CM, Ito T, Tanaka E, Tsunoda S, Nagayama S, Sakai Y, et al. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int J Cancer. 2008;122:325–32.CrossRefPubMed
21.
Zheng TS, Hong XH, Wang JB, Pei TM, Liang YJ, Yin DL, et al. Gankyrin promotes tumor growth and metastasis through activation of il-6/stat3 signaling in human cholangiocarcinoma. Hepatol (Baltim, Md). 2014;59:935–46.CrossRef
22.
Zheng JY, Hu H, Du JJ, Li XH, Zhao QC. P28gank is a novel marker for prognosis and therapeutic target in gastric cancer. Mol Biol. 2014;48:84–90.CrossRef
23.
Yang Y, Zhang CL, Li L, Gao YS, Luo XM, Zhang YD, Liu WP, Fei Z. Up-regulated oncoprotein p28gank correlates with proliferation and poor prognosis of human glioma. World J Surg Oncol 2012;10.
24.
Meng Y, He L, Guo X, Tang S, Zhao X, Du R, et al. Nie Y, liu J, Fan D: Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Lett. 2010;297:9–17.CrossRefPubMed
25.
Li J, Knobloch TJ, Kresty LA, Zhang Z, Lang JC, Schuller DE, et al. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res. 2011;31:2683–92.PubMed
26.
Wang GW, Rong JS, Zhou ZH, Duo JA. A novel gene p28gank confers multidrug resistance by modulating the expression of mdr-1, bcl-2, and bax in osteosarcoma cells. Mol Biol. 2010;44:898–906.CrossRef
27.
Zhang J, Yang Y, Zhang Z, He Y, Liu Z, Yu Y, et al. Gankyrin plays an essential role in estrogen-driven and gpr30-mediated endometrial carcinoma cell proliferation via the pten/pi3k/akt signaling pathway. Cancer Lett. 2013;339:279–87.CrossRefPubMed
28.
Kim KH, Lim HJ, Kim YJ, Kim SW, Kim YS, Tian C, et al. The oncoprotein, gankyrin, is up-regulated in middle ear cholesteatoma. Acta Otolaryngol. 2014;134:238–43.CrossRefPubMed
29.
Ando S, Matsuoka T, Kawai K, Sugita S, Joraku A, Kojima T, et al. Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor. Int J Urol. 2014;21:992–8.CrossRefPubMed
30.
Hwang J-A, Yang H-M, Hong D-P, Joo S-Y, Choi Y-L, Park J-H, et al. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. Oncotarget. 2014;5:9065–78.CrossRefPubMedPubMedCentral
31.
Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H et al. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the pi3k/akt/hif-1alpha/cyclin d1 pathway. Oncogene 2015.
32.
Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren YB, et al. P28gank prevents degradation of oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. Gastroenterology. 2012;142:1547–1558.e1514.CrossRefPubMed
33.
Jiang YJ, Iakova P, Jin JL, Sullivan E, Sharin V, Hong IH, et al. Farnesoid x receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatol (Baltim, Md). 2013;57:1098–106.CrossRef
34.
Luo T, Fu J, Xu A, Su B, Ren Y, Li N. et al. Psmd10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with atg7 and nuclear transactivation of atg7 expression. Autophagy 2015:0.
35.
Li X, Zhang Y, Xiong C, Jin H, Jing B, Zhang Y, et al. Overexpression of a new gene p28gank confers multidrug resistance of gastric cancer cells. Cancer Investig. 2009;27:129–39.CrossRef
36.
Chen X, Zhang M, Liu LX. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep 2009;22.
37.
Downward J. Mechanisms and consequences of activation of protein kinase b/akt. Curr Opin Cell Biol. 1998;10:262–7.CrossRefPubMed
38.
Lim KH, Counter CM. Reduction in the requirement of oncogenic ras signaling to activation of pi3k/akt pathway during tumor maintenance. Cancer Cell. 2005;8:381–92.CrossRefPubMed
39.
Parsons R, Simpson L. Pten and cancer; in El-Deiry W (ed) Tumor suppressor genes. Humana Press. 2003;222:147–66.
40.
41.
42.
DerMardirossian C, Bokoch GM. Gdis: Central regulatory molecules in rho gtpase activation. Trends Cell Biol. 2005;15(7):356–63.CrossRefPubMed
43.
Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, et al. Regulation of pten by rho small gtpases. Nat Cell Biol. 2005;7:399–404.CrossRefPubMed
44.
45.
Sanchez T, Thangada S, Wu M-T, Kontos CD, Wu D, Wu H, et al. Pten as an effector in the signaling of antimigratory g protein-coupled receptor. Proc Natl Acad Sci U S A. 2005;102:4312–7.CrossRefPubMedPubMedCentral
46.
Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, et al. P28gank overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/akt/hypoxia-inducible factor-1alpha pathways. Hepatology. 2011;53:181–92.CrossRefPubMed
47.
48.
Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol. 2002;4:E101–8.CrossRefPubMed
49.
Taipale J, Beachy PA. The hedgehog and wnt signalling pathways in cancer. Nature. 2001;411:349–54.CrossRefPubMed
50.
Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, et al. The oncoprotein p28(gank) establishes a positive feedback loop in beta-catenin signaling. Cell Res. 2011;21:1248–61.CrossRefPubMedPubMedCentral
51.
Bai Z, Tai Y, Li W, Zhen C, Gu W, Jian Z, et al. Gankyrin activates il-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013;73:4548–58.CrossRefPubMed
52.
Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D. et al. Lbh589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway. Mol Cancer 2013;12.
53.
Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1991;88:7605–9.CrossRefPubMedPubMedCentral
54.
Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia. 1994;8:1982–8.PubMed
55.
Church LD, Cook GP, McDermott MF. Primer: Inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42.CrossRefPubMed
56.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. Nf-kappab functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.CrossRefPubMed
57.
Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of nemo/ikkgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–32.CrossRefPubMed
58.
Karin M, Cao Y, Greten FR, Li ZW. Nf-kappab in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRefPubMed
59.
Karin M. The ikappab kinase - a bridge between inflammation and cancer. Cell Res. 2008;18:334–42.CrossRefPubMed
60.
61.
Su B, Luo T, Zhu J, Fu J, Zhao X, Chen L, et al. Interleukin-1beta/iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis. Hepatology. 2015;61:585–97.CrossRefPubMed
62.
Higashitsuji H, Higashitsuji H, Liu Y, Masuda T, Fujita T, Abdel-Aziz HI, et al. The oncoprotein gankyrin interacts with rela and suppresses nf-(kappa)b activity. Biochem Biophys Res Commun. 2007;363:879–84.CrossRefPubMed
63.
Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong LW, et al. Oncoprotein p28 gank binds to rela and retains nf-kappab in the cytoplasm through nuclear export. Cell Res. 2007;17:1020–9.CrossRefPubMed
64.
Ren YB, Luo T, Li J, Fu J, Wang Q, Cao GW, et al. P28(gank) associates with p300 to attenuate the acetylation of rela. Mol Carcinog. 2015;54:1626–35.CrossRefPubMed
65.
Chapman AM, McNaughton BR. Synthetic proteins potently and selectively bind the oncoprotein gankyrin, modulate its interaction with s6 atpase, and suppress gankyrin/mdm2-dependent ubiquitination of p53. ACS Chem Biol. 2015;10:1880–6.CrossRefPubMedPubMedCentral
66.
Thakur PK, Hassan MI. Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach. Int J Comput Biol Drug Des. 2011;4:373–86.CrossRefPubMed
67.
Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, et al. Mir-605 represses psmd10/gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014;588:3491–500.CrossRefPubMed
68.
Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T, et al. Restoration of microrna-214 expression reduces growth of myeloma cells through positive regulation of p53 and inhibition of DNA replication. Haematologica. 2013;98:640–8.CrossRefPubMedPubMedCentral
Metadata
Title
Gankyrin regulates cell signaling network
Authors
Xinxin Wang
Bin Jiang
Yanjie Zhang
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4854-z

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2

Original Article

Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway

Original Article

Gene polymorphisms and oral cancer risk in tobacco habitués

Original Article

MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1

Erratum

Erratum to: FAM98A is a novel substrate of PRMT1 required for tumor cell migration, invasion and colony formation

Original Article

Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits